VIS 649

Drug Profile

VIS 649

Alternative Names: VIS649

Latest Information Update: 07 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Visterra
  • Developer Juntendo University; Visterra
  • Class Monoclonal antibodies
  • Mechanism of Action B-cell maturation antigen modulators; Immunomodulators; Transmembrane activator and CAML interactor protein modulators; Tumour necrosis factor ligand superfamily member 13 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical IgA nephropathy

Most Recent Events

  • 31 Oct 2017 Preclinical trials in IgA nephropathy in Japan (Parenteral) before October 2017
  • 05 Oct 2017 VIS 649 is available for licensing as of 05 Oct 2017. http://www.visterrainc.com
  • 31 Mar 2017 Visterra plans a phase I trial for IgA nephropathy in USA in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top